The use of tadalafil in the treatment of lower urinary tract symptoms among men suffering from benign prostatic hyperplasia, on the example of the population of the Greater Poland province
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License.
Parsons J.K.: Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. Curr Bladder Dysfunct Rep. 2010 Dec;5(4):212-218. doi: 10.1007/s11884-010-0067-2. Epub 2010 Sep 7. PMID: 21475707; PMCID: PMC3061630.Search in Google Scholar
Wei J.T., Calhoun E., Jacobsen S.J.: Urologic diseases in America project: benign prostatic hyper-plasia. J Urol. 2005 Apr;173(4):1256-61. doi: 10.1097/01.ju.0000155709.37840.fe. PMID: 15758764.Search in Google Scholar
Lepor H.: Pathophysiology of lower urinary tract symptoms in the aging male population. Rev Urol. 2005;7 Suppl 7(Suppl 7):S3-S11. PMID: 16986059; PMCID: PMC1477625.Search in Google Scholar
Berry S.J., Coffey D.S., Walsh P.C., Ewing L.L.: The development of human benign prostatic hyper-plasia with age. J Urol. 1984 Sep;132(3):474-9. doi: 10.1016/s0022-5347(17)49698-4. PMID: 6206240.Search in Google Scholar
Da Silva F.C.: Benign prostatic hyperplasia: natural evolution versus medical treatment. Eur Urol. 1997;32 Suppl 2:34-7. PMID: 9248811.Search in Google Scholar
Napalkov P., Maisonneuve P., Boyle P.: Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia. Urology. 1995 Sep;46(3 Suppl A):41-6. doi: 10.1016/s0090-4295(99)80249-0. PMID: 7544516.Search in Google Scholar
Kant P., Inbaraj L.R., Franklyn N.N., Norman G.: Prevalence, risk factors and quality of life of Lower Urinary Tract Symptoms (LUTS) among men attending Primary Care slum clinics in Bangalore: A cross-sectional study. J Family Med Prim Care. 2021 Jun;10(6):2241-2245. doi: 10.4103/jfmpc. jfmpc_2316_20. Epub 2021 Jul 2. PMID: 34322419; PMCID: PMC8284223.Search in Google Scholar
Welch G., Weinger K., Barry M.J.: Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology. 2002 Feb;59(2):245-50. doi: 10.1016/ s0090-4295(01)01506-0. PMID: 11834396.Search in Google Scholar
Coyne K.S., Wein A.J., Tubaro A., Sexton C.C., Thompson C.L., Kopp Z.S., Aiyer L.P.: The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int. 2009 Apr;103 Suppl 3:4-11. doi: 10.1111/j.1464-410X.2009.08371.x. PMID: 19302497.Search in Google Scholar
Plochocki A., King B.: Medical Treatment of Benign Prostatic Hyperplasia. Urol Clin North Am. 2022 May;49(2):231-238. doi: 10.1016/j.ucl.2021.12.003. Epub 2022 Mar 22. PMID: 35428429.Search in Google Scholar
Gacci M., Corona G., Salvi M., Vignozzi L., McVary K.T., Kaplan S.A., Roehrborn C.G., Serni S., Mirone V., Carini M., Maggi M.: A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012 May;61(5):994-1003. doi: 10.1016/j.eururo.2012.02.033. Epub 2012 Feb 25. PMID: 22405510.Search in Google Scholar
Cellek S., Cameron N.E., Cotter M.A., Fry C.H., Ilo D.. Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS. Nat Rev Urol. 2014 Apr;11(4):231-41. doi: 10.1038/nrurol.2014.53. Epub 2014 Mar 11. PMID: 24619381.Search in Google Scholar
Mónica F.Z., De Nucci G.: Tadalafil for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother. 2019 Jun;20(8):929-937. doi: 10.1080/14656566.2019.1589452. Epub 2019 Mar 22. PMID: 30901259.Search in Google Scholar
Kallidonis P., Adamou C., Kotsiris D., Ntasiotis P., Verze P., Athanasopoulos A.: Young Academic Urologists of the European Association of Urology-Endourology Working Party. Combination Therapy with Alpha-blocker and Phosphodiesterase-5 Inhibitor for Improving Lower Urinary Tract Symptoms and Erectile Dysfunction in Comparison with Monotherapy: A Systematic Review and Meta-analysis. Eur Urol Focus. 2020 May 15;6(3):537-558. doi: 10.1016/j.euf.2019.05.007. Epub 2019 May 25. PMID: 31133414.Search in Google Scholar
Sun K., Sun F., Yao H., Zhang D., Wu G., Wang T., Wang J., Wu J.: Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis. Am J Mens Health. 2020 Nov-Dec;14(6):1557988320980180. doi: 10.1177/1557988320980180. PMID: 33342335; PMCID: PMC7756049.Search in Google Scholar
Kolontarev K., Govorov A., Kasyan G., Priymak D., Pushkar D.: Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors. Cent European J Urol. 2016;69(4):398-403. doi: 10.5173/ceju.2016.879. Epub 2016 Nov 30. PMID: 28127458; PMCID: PMC5260456.Search in Google Scholar
Abdel-Aziz A.A., Asiri Y.A., El-Azab A.S., Al-Omar M.A., Kunieda T.: Tadalafil. Profiles Drug Subst Excip Relat Methodol. 2011;36:287-329. doi: 10.1016/B978-0-12-387667-6.00008-7. Epub 2011 Jun 23. PMID: 22469265.Search in Google Scholar
Morelli A., Sarchielli E., Comeglio P., Filippi S., Mancina R., Gacci M., Vignozzi L., Carini M., Vannelli G.B., Maggi M.: Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med. 2011 Oct;8(10):2746-60. doi: 10.1111/j.1743-6109.2011.02416.x. Epub 2011 Aug 3. PMID: 21812935.Search in Google Scholar
Fibbi B., Morelli A., Vignozzi L., Filippi S., Chavalmane A., De Vita G., Marini M., Gacci M., Vannelli G.B., Sandner P., Maggi M.: Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med. 2010 Jan;7(1 Pt 1):59-69. doi: 10.1111/j.1743-6109.2009.01511.x. Epub 2009 Sep 29. PMID: 19796053.Search in Google Scholar
Mora A.G., Andrade D.R., Janussi S.C., Goncalves T.T., Krikorian K., Priviero F.B.M., Claudino M.A.: Tadalafil treatment improves cardiac, renal and lower urinary tract dysfunctions in rats with heart failure. Life Sci. 2022 Jan 15;289:120237. doi: 10.1016/j.lfs.2021.120237. Epub 2021 Dec 16. PMID: 34922942.Search in Google Scholar
Zahir M., Samzadeh M., Poopak A., Khoshdel A.R., Armin A.: Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial. Urol J. 2023 Jul 26;20(4):255-260. doi: 10.22037/uj.v20i.7593. PMID: 37245088.Search in Google Scholar
Gotoh D., Torimoto K., Morizawa Y., Hori S., Nakai Y., Miyake M., Fujimoto K.: Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia. BMC Res Notes. 2022 Sep 5;15(1):288. doi: 10.1186/s13104-022-06183-0. PMID: 36064733; PMCID: PMC9446813.Search in Google Scholar
Kuno T., Tamura K., Fukuhara H., Fukata S., Ashida S., Karashima T., Sawada K., Yasuda M., Watanabe H., Komatsu F., Kuroiwa H., Saito M., Inoue K.: Tadalafil 5 mg Once Daily Improved Each IPSS Subscore, QOL, and Nocturia in Elderly BPH Patients over 70 Years Old in a Real-World Clinical Setting. Urol Int. 2022;106(10):1005-1011. doi: 10.1159/000519476. Epub 2021 Oct 21. PMID: 34673648.Search in Google Scholar
Ahmad M.S., Dar Y.A., Khawaja A.R., Para S.A., Malik S.A., Wani M.S., Bhat A.H., Wani P.M.: Comparative study of tamsulosin versus tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms. A prospective randomized study. Urol Ann. 2022 Jul-Sep;14(3):236-240. doi: 10.4103/ua.ua_6_21. Epub 2022 Apr 14. PMID: 36117785; PMCID: PMC9472311.Search in Google Scholar
Singh I., Tk A., Gupta S.: Efficacy and safety of tadalafil vs tamsulosin in lower urinary tract symptoms (LUTS) as a result of benign prostate hyperplasia (BPH)-open label randomised controlled study. Int J Clin Pract. 2020 Aug;74(8):e13530. doi: 10.1111/ijcp.13530. Epub 2020 Jun 15. PMID: 32542854.Search in Google Scholar
Takahashi R., Sumino Y., Miyazato M., Nishii H., Oshiro T., Mimata H., Saito S., Yoshida M., Eto M.: Tadalafil Improves Nocturia and Nocturia-Related Quality of Life in Patients with Benign Prostatic Hyperplasia (KYU-PRO Study). Urol Int. 2020;104(7-8):587-593. doi: 10.1159/000506489. Epub 2020 Jun 2. PMID: 32485724.Search in Google Scholar
Tawfik A., Abo-Elenen M., Gaber M., El-Abd A., Zoeir A., Saad S., Sultan I., Ghoneim A.: Tadalafil versus tamsulosin as combination therapy with 5-alpha reductase inhibitors in benign prostatic hyper-plasia, urinary and sexual outcomes. World J Urol. 2024 Feb 3;42(1):70. doi: 10.1007/s00345-023-04735-y. PMID: 38308714.Search in Google Scholar
Kosilov K., Kuzina I., Kuznetsov V., Barabash O., Fedorishcheva E.: Efficacy of a combination of dutasteride, tadalafil, and solifenacin in the treatment of previously unsuccessful patients. Asian J Urol. 2022 Jan;9(1):42-50. doi: 10.1016/j.ajur.2021.04.002. Epub 2021 Apr 20. Erratum in: Asian J Urol. 2023 Jan;10(1):117-118. doi: 10.1016/j.ajur.2022.11.001. PMID: 35198395; PMCID: PMC8841250.Search in Google Scholar
AbdelRazek M., Abolyosr A., Mhammed O., Fathi A., Talaat M., Hassan A.: Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. World J Urol. 2022 Aug;40(8):2063-2070. doi: 10.1007/s00345-022-04071-7. Epub 2022 Jun 30. Erratum in: World J Urol. 2024 Jul 22;42(1):434. doi: 10.1007/s00345-024-05164-1. PMID: 35773357; PMCID: PMC9279271.Search in Google Scholar
Sebastianelli A., Spatafora P., Morselli S., Vignozzi L., Serni S., McVary K.T., Kaplan S., Gravas S., Chapple C., Gacci M.: Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED. Curr Urol Rep. 2020 Oct 27;21(12):56. doi: 10.1007/s11934-020-01009-7. PMID: 33108544; PMCID: PMC7591403.Search in Google Scholar
Liu J., Zhou W., Zhang P., Zhang W., Chang C., Fu G.: Comparison of Monotherapies and Combination Therapy of Tamsulosin and Tadalafil for Treating Lower Urinary Tract Symptoms Caused by Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Meta-Analysis. Urol Int. 2024;108(2):89-99. doi: 10.1159/000535606. Epub 2023 Dec 11. PMID: 38081154.Search in Google Scholar
Jackson E.M., Khooblall P., Lundy S.D., Bajic P.: A Review of Combined Phosphodiesterase-5-Inhibitors and α-Blockers versus Phosphodiesterase-5-Inhibitors Alone for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia. Arab J Urol. 2023 Jun 13;22(1):13-23. doi: 10.1080/2090598X.2023.2220627. PMID: 38205391; PMCID: PMC10776071.Search in Google Scholar
Guo B., Chen X., Wang M., Hou H., Zhang Z., Liu M.: Comparative Effectiveness of Tadalafil versus Tamsulosin in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: A Meta-Analysis of Randomized Controlled Trials. Med Sci Monit. 2020 Apr 24;26:e923179. doi: 10.12659/MSM.923179. PMID: 32327621; PMCID: PMC7195607.Search in Google Scholar
Zhou R., Che X., Zhou Z., Ma Y.: A Systematic Review and Meta-Analysis of the Efficacy and Safety of Tamsulosin Plus Tadalafil Compared With Tamsulosin Alone in Treating Males With Lower Urinary Tract Symptoms Secondary to Benign Prostrate Hyperplasia. Am J Mens Health. 2023 Jan-Feb;17(1) :15579883231155096. doi: 10.1177/15579883231155096. PMID: 36842963; PMCID: PMC9972064.Search in Google Scholar
Cui J., Cao D., Bai Y., Wang J., Yin S., Wei W., Xiao Y., Wang J., Wei Q.: Efficacy and Safety of 12-week Monotherapy With Once Daily 5 mg Tadalafil for Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: Evidence-based Analysis. Front Med (Lausanne). 2021 Oct 12;8:744012. doi: 10.3389/fmed.2021.744012. PMID: 34712682; PMCID: PMC8545998.Search in Google Scholar
Kloner R.A., Kostis J.B., McGraw T.P., Qiu C., Gupta A.: Analysis of integrated clinical safety data of tadalafil in patients receiving concomitant antihypertensive medications. J Clin Hypertens (Greenwich). 2022 Feb;24(2):167-178. doi: 10.1111/jch.14435. Epub 2022 Jan 31. PMID: 35099113; PMCID: PMC8845471.Search in Google Scholar
Ma C., Zhang J., Cai Z., Xiong J., Li H.. Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis. Biomed Res Int. 2020 Mar 26;2020:1419520. doi: 10.1155/2020/1419520. PMID: 32309423; PMCID: PMC7140123.Search in Google Scholar
